Brief: Successful CANTOS Inflammation Trial supports rationale for Resverlogix' ongoing betonmace trial

Resverlogix

29/08/2017 17:58

Aug 29 (Reuters) - Resverlogix Corp  
    * under CANTOS trial treatment with Resverlogix' apabetalone 
has demonstrated a reduction in inflammatory mediator il-6 by 29 
percent 
 
Source text for Eikon:  ID:nCNWRxzY7a  
Further company coverage:  NOVN.S  
 
 ((Bangalore.newsroom@thomsonreuters.com;))